Pilot Double-Blind Randomised Controlled Trial: Effects of Jejunal Nutrition on Postprandial Distress in Diabetic Gastropathy (J4G Trial).
MRI
diabetic gastropathy
gastric emptying
gastroparesis
jejunal nutrition
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
22 Mar 2022
22 Mar 2022
Historique:
received:
18
02
2022
revised:
13
03
2022
accepted:
18
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Nausea, vomiting and abdominal pain in diabetic patients are often attributed to diabetic gastropathy (DG). Post-pyloric (“jejunal”) enteral nutrition (JN) may improve nutrition and glycaemia in difficult cases. The acute effects of JN on postprandial symptoms and gastric function in DG patients has not been studied. DG patients with moderate to severe symptoms (gastroparesis cardinal symptom index (GCSI) > 27), diabetic controls without symptoms (DC; GCSI < 14) and healthy controls (HV) were entered into a randomized, double blind controlled trial. JN with liquid nutrient (2 kcal/min) or water was infused for 60 min prior to ingestion of a standardized mixed solid/liquid test meal. Outcomes included postprandial symptoms and effects on gastrointestinal (GI)−peptide hormones and gastric emptying (GE) assessed by magnetic resonance imaging (MRI). Nine DG, nine DC and twelve HV were recruited. DG patients reported more symptoms after meals than other groups (p < 0.05). Post-prandial symptoms were reduced after JN in DG patients (p < 0.01). GE was more rapid after JN in DG and DC patients (p < 0.05). JN induced a GI−peptide response in all subjects; however, this was less pronounced in diabetic groups. JN has beneficial effects on DG patients’ symptoms after a meal. The mechanism is not primarily mediated by effects on GE, but appears to involve other aspects of GI function, including visceral sensitivity.
Identifiants
pubmed: 35405934
pii: nu14071321
doi: 10.3390/nu14071321
pmc: PMC9000869
pii:
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Swiss National Science Foundation
ID : 320030-120597
Pays : Switzerland
Références
Aliment Pharmacol Ther. 2019 Jul;50(1):24-32
pubmed: 31107579
Diabetes Care. 2000 Mar;23(3):426-7
pubmed: 10868883
Neurogastroenterol Motil. 2019 Nov;31(11):e13697
pubmed: 31448521
Gastroenterology. 2021 May;160(6):2006-2017
pubmed: 33548234
Surg Endosc. 2013 Jan;27(1):61-6
pubmed: 22752276
Gut. 1988 Aug;29(8):1042-51
pubmed: 3410330
Aliment Pharmacol Ther. 2003 Sep 15;18(6):569-80
pubmed: 12969083
Gut. 1995 Jul;37(1):23-9
pubmed: 7672674
Aliment Pharmacol Ther. 2009 Sep 15;30(6):670-80
pubmed: 19558608
Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38
pubmed: 23147521
Aliment Pharmacol Ther. 2007 Nov 1;26(9):1251-8
pubmed: 17944739
Aliment Pharmacol Ther. 2003 Jul 1;18(1):141-50
pubmed: 12848636
Gut. 2019 May;68(5):804-813
pubmed: 29860241
Circulation. 2009 Apr 7;119(13):1694-6
pubmed: 19349331
Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G844-9
pubmed: 11292591
Scand J Gastroenterol. 1998 Mar;33(3):236-41
pubmed: 9548614
Am J Physiol. 1999 Mar;276(3):G761-6
pubmed: 10070054
Neurogastroenterol Motil. 2016 Apr;28(4):554-68
pubmed: 26863609
Neurogastroenterol Motil. 2018 Dec;30(12):e13463
pubmed: 30216596
Am J Gastroenterol. 2019 Jan;114(1):143-154
pubmed: 30166634
Phys Med Biol. 2015 Feb 7;60(3):1367-83
pubmed: 25592405
Dig Dis Sci. 1992 May;37(5):744-50
pubmed: 1563318
Dig Dis Sci. 1998 Mar;43(3):491-6
pubmed: 9539642
Am J Physiol Gastrointest Liver Physiol. 2009 Nov;297(5):G894-901
pubmed: 19779010
Dig Dis Sci. 1996 Jan;41(1):9-16
pubmed: 8565773
Eur J Clin Invest. 1984 Dec;14(6):420-7
pubmed: 6441717